Tag:

Pacific Biosciences

Latest Headlines

Latest Headlines

Buzz: Roche weighing up bid for Pacific Biosciences

Roche is reportedly considering continuing its sequencing dealmaking activity with a bid for Pacific Biosciences.

Roche reportedly pursuing buyout of genomics company Pacific Biosciences of California

Shares of Menlo Park's Pacific Biosciences of California are up 25% on a report that Big Pharma (and diagnostics) player Roche is interested in acquiring the provider of gene sequencing technology.

PacBio soars on news of cheaper, smaller, higher-throughput sequencer

Pacific Biosciences has stepped up the fight for the sequencing market with the introduction of an instrument that is smaller, cheaper and higher throughput than the model it replaces.

RainDance shoots for long reads of whole genome with Pac Bio collaboration

As industry heavyweights develop innovative technologies for longer reads of the human genome, RainDance Technologies and Pacific Biosciences are joining forces for a new project aimed at de novo whole-genome assembly.

RainDance shoots for long reads of whole genome with Pac Bio collaboration

As industry heavyweights develop innovative technologies for longer reads of the human genome, RainDance Technologies and Pacific Biosciences are joining forces for a new project aimed at de novo whole-genome assembly.

RainDance Technologies and Pacific Biosciences partner for whole genome assembly

RainDance Technologies and Pacific Biosciences are teaming up for de novo whole genome assembly as RainDance chases its previously announced IPO.

RainDance Technologies and Pacific Biosciences partner for whole genome assembly

RainDance Technologies and Pacific Biosciences are teaming up for de novo whole genome assembly as RainDance chases its previously announced IPO.

Roche, Pacific Biosciences seal $75M clinical Dx partnership

Struggling gene sequencer Pacific Biosciences signed a diagnostics product-development deal with industry giant Roche worth as much as $75 million.

PacBio soars in wake of $75M Dx deal with Roche

Struggling gene sequencer Pacific Biosciences saw its stock rocket upward in the wake of a diagnostics development deal with industry giant Roche that's worth as much as $75 million, closing at $5.98 on Sept. 25, a jump of more than 72.8%.

Roche, Pacific Biosciences forge clinical Dx deal

Roche's massive diagnostics division has signed on with yet another development partner: California's Pacific Biosciences, which focuses on gene sequencing. The pair will develop diagnostics products for clinical research.
'